|
WO2008023161A1
(en)
*
|
2006-08-23 |
2008-02-28 |
Kudos Pharmaceuticals Limited |
2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
|
|
AU2008227979B2
(en)
*
|
2007-03-16 |
2014-02-06 |
Actelion Pharmaceuticals Ltd |
Amino- pyridine derivatives as S1P1 /EDG1 receptor agonists
|
|
US20080234262A1
(en)
*
|
2007-03-21 |
2008-09-25 |
Wyeth |
Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
|
|
US9029411B2
(en)
|
2008-01-25 |
2015-05-12 |
Millennium Pharmaceuticals, Inc. |
Thiophenes and uses thereof
|
|
PT3216793T
(pt)
|
2008-05-23 |
2019-05-30 |
Wyeth Llc |
Compostos de triazina como inibidores de pi3 quinase e mtor
|
|
UY32138A
(es)
|
2008-09-25 |
2010-04-30 |
Boehringer Ingelheim Int |
Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
|
|
US9090601B2
(en)
|
2009-01-30 |
2015-07-28 |
Millennium Pharmaceuticals, Inc. |
Thiazole derivatives
|
|
JP2012516329A
(ja)
*
|
2009-01-30 |
2012-07-19 |
ミレニアム ファーマシューティカルズ， インコーポレイテッド |
Ｐｉ３ｋ阻害剤としてのヘテロアリールおよびその使用
|
|
UY32470A
(es)
|
2009-03-05 |
2010-10-29 |
Boehringer Ingelheim Int |
Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
|
|
US8242260B2
(en)
|
2009-08-28 |
2012-08-14 |
Novartis Ag |
Compounds and compositions as protein kinase inhibitors
|
|
WO2011067348A2
(en)
|
2009-12-03 |
2011-06-09 |
Novartis Ag |
Mek inhibitor salts and solvates thereof
|
|
WO2011067356A2
(en)
|
2009-12-03 |
2011-06-09 |
Novartis Ag |
Polymorphs of a mek inhibitor
|
|
PH12012501581A1
(en)
|
2010-02-03 |
2012-10-22 |
Signal Pharm Llc |
Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
|
|
GB201004200D0
(en)
|
2010-03-15 |
2010-04-28 |
Univ Basel |
Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
|
|
WO2011120911A1
(en)
|
2010-03-30 |
2011-10-06 |
Novartis Ag |
Pkc inhibitors for the treatment of b-cell lymphoma having chronic active b-cell-receptor signalling
|
|
US20130035336A1
(en)
|
2010-04-13 |
2013-02-07 |
Novartis Ag |
Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor for treating cancer
|
|
EA201201676A1
(ru)
|
2010-06-25 |
2013-06-28 |
Новартис Аг |
Гетероарильные соединения и композиции в качестве ингибиторов протеинкиназы
|
|
US9062038B2
(en)
|
2010-08-11 |
2015-06-23 |
Millennium Pharmaceuticals, Inc. |
Heteroaryls and uses thereof
|
|
US8586604B2
(en)
|
2010-08-20 |
2013-11-19 |
Boehringer Ingelheim International Gmbh |
Inhibitors of the microsomal prostaglandin E2 synthase-1
|
|
US8759537B2
(en)
|
2010-08-20 |
2014-06-24 |
Boehringer Ingelheim International Gmbh |
3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
|
|
US8674113B2
(en)
|
2010-12-10 |
2014-03-18 |
Boehringer Ingelheim International Gmbh |
Compounds
|
|
US8486968B2
(en)
|
2010-12-10 |
2013-07-16 |
Boehringer Ingelheim International Gmbh |
Compounds
|
|
US8466186B2
(en)
|
2010-12-10 |
2013-06-18 |
Boehringer Ingelheim International Gmbh |
Compounds
|
|
CN103857804A
(zh)
|
2011-08-03 |
2014-06-11 |
西格诺药品有限公司 |
作为lkb1状态的预测性生物标志物的基因表达谱的鉴定
|
|
JP6026544B2
(ja)
|
2011-09-27 |
2016-11-16 |
ノバルティス アーゲー |
変異体ｉｄｈの阻害剤としての３−ピリミジン−４−イル−オキサゾリジン−２−オン類
|
|
WO2013082344A1
(en)
*
|
2011-12-02 |
2013-06-06 |
Signal Pharmaceuticals, Llc |
Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
|
|
UY34632A
(es)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
Compuestos de oxazolidin- 2- ona y usos de los mismos
|
|
AU2013203714B2
(en)
|
2012-10-18 |
2015-12-03 |
Signal Pharmaceuticals, Llc |
Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
|
|
US9296733B2
(en)
|
2012-11-12 |
2016-03-29 |
Novartis Ag |
Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
|
|
JP6120311B2
(ja)
*
|
2013-02-12 |
2017-04-26 |
学校法人銀杏学園 |
ポリフェノール化合物
|
|
WO2014141104A1
(en)
|
2013-03-14 |
2014-09-18 |
Novartis Ag |
3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
|
|
EP2986609B1
(en)
|
2013-04-17 |
2019-06-19 |
Signal Pharmaceuticals, LLC |
Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
|
|
EA030808B1
(ru)
|
2013-04-17 |
2018-09-28 |
СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи |
ПРИМЕНЕНИЕ 1-ЭТИЛ-7-(2-МЕТИЛ-6-(1Н-1,2,4-ТРИАЗОЛ-3-ИЛ)ПИРИДИН-3-ИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1Н)-ОНА В ЛЕЧЕНИИ МУЛЬТИФОРМНОЙ ГЛИОБЛАСТОМЫ
|
|
US9474757B2
(en)
|
2013-04-17 |
2016-10-25 |
Signal Pharmaceuticals, Llc |
Methods for treating cancer using TOR kinase inhibitor combination therapy
|
|
MX2015014455A
(es)
|
2013-04-17 |
2016-07-21 |
Signal Pharm Llc |
Terapia de combinacion que comprende un inhibidor de tor cinasa y n-(3-(5-fluoro-2-(4-(2-metoxietoxi)fenilamino)pirimidin-4-ilamino )fenil)acrilamida para tratar cancer.
|
|
NZ631082A
(en)
|
2013-04-17 |
2017-06-30 |
Signal Pharm Llc |
Methods for treating cancer using tor kinase inhibitor combination therapy
|
|
BR112015026292B1
(pt)
|
2013-04-17 |
2022-04-12 |
Signal Pharmaceuticals, Llc |
Uso de 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-il)piridin-3-il)-3,4-dihidropirazino [2,3-b]pirazin-2(1h)- ona e métodos in vitro
|
|
MY189663A
(en)
|
2013-04-17 |
2022-02-23 |
Signal Pharm Llc |
Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
|
|
JP6401250B2
(ja)
|
2013-05-29 |
2018-10-10 |
シグナル ファーマシューティカルズ，エルエルシー |
７−（６−（２−ヒドロキシプロパン−２−イル）ピリジン−３−イル）−１−（（ｔｒａｎｓ）−４−メトキシシクロヘキシル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン、その固体形態の医薬組成物、及びその使用方法
|
|
EP3105229A4
(en)
|
2014-02-14 |
2017-12-20 |
The University of British Columbia |
Human androgen receptor dna-binding domain (dbd) compounds as therapeutics and methods for their use
|
|
NZ714742A
(en)
|
2014-04-16 |
2017-04-28 |
Signal Pharm Llc |
Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
|
|
EP3131551A4
(en)
|
2014-04-16 |
2017-09-20 |
Signal Pharmaceuticals, LLC |
SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
|
|
MX2019015731A
(es)
|
2017-06-22 |
2020-08-03 |
Celgene Corp |
Tratamiento de carcinoma hepatocelular caracterizado por infeccion por virus de hepatitis b.
|
|
WO2021247859A1
(en)
*
|
2020-06-03 |
2021-12-09 |
Yumanity Therapeutics, Inc. |
Pyridopyrimidines and methods of their use
|
|
AU2024288001A1
(en)
|
2023-07-11 |
2026-01-15 |
Tay Therapeutics Limited |
Compounds comprising a naphthyridine or pyridopyrimidine core as ptc read-through agents
|